D. Kontoyiannis
Infectious Diseases · 2003–2019
A researcher in the Science corpus: 13 papers; trusts 2 researchers and is trusted by 3 researchers here, as inferred from the citation graph.
Subfields
- Infectious Diseases — 85 citations into it; #266 of 589 by trust here, #115 by citations
- Epidemiology — 79 citations into it; #1,496 of 2,148 by trust here, #558 by citations
- Cell Biology — 14 citations into it
Whom D. Kontoyiannis trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts D. Kontoyiannis overall
Papers from D. Kontoyiannis's perspective
Ordered by how strongly the researchers D. Kontoyiannis trusts endorse each paper. Same corpus, a different order for every researcher.
- Zygomycetes in human disease. (Clinical Microbiology Reviews)
- Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. (New England Journal of Medicine)
- Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. (New England Journal of Medicine)
- Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. (New England Journal of Medicine)
- Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. (The Lancet)
- Delaying the Empiric Treatment of Candida Bloodstream Infection until Positive Blood Culture Results Are Obtained: a Potential Risk Factor for Hospital Mortality (Antimicrobial Agents and Chemotherapy)
- 2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer
- Anidulafungin versus fluconazole for invasive candidiasis. (New England Journal of Medicine)
- Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. (Clinical Infectious Diseases)
- Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. (Clinical Infectious Diseases)
Their papers
- Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium (2019) — 2,463 citations
- Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. (2016) — 849 citations
- Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. (2016) — 2,332 citations
- Pathogenesis of mucormycosis. (2012) — 722 citations
- Epidemiology and clinical manifestations of mucormycosis. (2012) — 1,274 citations
- Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). (2010) — 1,457 citations
- Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. (2010) — 1,417 citations
- Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. (2008) — 769 citations
- Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. (2008) — 2,622 citations
- Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. (2006) — 604 citations
- Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. (2005) — 675 citations
- Epidemiology and outcome of zygomycosis: a review of 929 reported cases. (2005) — 2,922 citations
- Glucocorticoids and invasive fungal infections. (2003) — 629 citations